A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs RPh 201 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Regenera Pharma
- 13 Jun 2019 Planned End Date changed from 30 Apr 2019 to 30 Jul 2020.
- 13 Jun 2019 Planned primary completion date changed from 28 Feb 2019 to 28 Dec 2019.
- 02 Aug 2018 According to a Regenera media release, the data from this study is expected in Q2 2019.